PASG

Passage Bio Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$14.96M
P/E Ratio
EPS
$-11.08
Beta
1.43
52W High
$20.00
52W Low
$3.29
50-Day MA
$4.62
200-Day MA
$7.62
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Passage Bio Inc

Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-37.58M
Operating Margin0.00%
Return on Equity-169.10%
Return on Assets-45.60%
Revenue/Share (TTM)$0.00
Book Value$1.39
Price-to-Book3.43
Price-to-Sales (TTM)
EV/Revenue-
EV/EBITDA0.87
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$3.22M
Float$3.20M
% Insiders7.71%
% Institutions46.41%

Historical Volatility

HV 10-Day
67.42%
HV 20-Day
50.18%
HV 30-Day
48.40%
HV 60-Day
85.95%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($15.50 target)
1
Buy
2
Hold

Latest News

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PASG and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026